VAUGHAN, Ontario / May 14, 2025 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of Zenlens CHROMA HOA scleral contact lenses. Designed to correct advanced higher-order aberrations (HOA), this custom, wavefront-guided scleral lens technology delivers enhanced vision and improves clarity by reducing symptoms such as halos and glare.
“Zenlens CHROMA HOA is a high-quality, customizable lens that fills a critical gap in scleral lens vision correction, especially for patients with complex corneal irregularities,” said Yang Yang, president, Global Vision Care, Bausch + Lomb. “Eye care professionals in the U.S. now have a new solution for patients that previously had limited options to improve vision quality.”
HOA correction starts with a secure lens fit1, which can be achieved through proprietary Zenlens technologies, including SmartCurve™ and Bi-Elevation™. Once lens stability is secured, custom HOA correction is applied to the lens to effectively reduce higher-order aberrations and enhance vision by minimizing blurring and distortion.
“For years, I’ve had patients who struggle with visual distortions caused by higher-order aberrations, and there was little I could do beyond basic correction,” said Jason Jedlicka, OD, chief of cornea and contact lens service and clinical professor, Indiana University School of Optometry. “With Zenlens CHROMA HOA, I can offer a level of precision that wasn’t previously possible, and my patients can experience sharper vision and improved clarity, which has a significant impact on their quality of life.”
Bausch + Lomb is collaborating with Advance Medical and OVITZ® to help eye care professionals integrate Zenlens CHROMA HOA into their practices. Advance Medical’s FocalPoints® software platform – a leading platform for specialty lens manufacturing – enables seamless and precise production of the Zenlens CHROMA HOA design. OVITZ, the first company to develop an aberrometry system specifically for HOA correction, is providing its latest device, the xwave aberrometer.
For more information on Zenlens CHROMA HOA, visit www.bauschsvp.com/lenses/zenlens.
Important Safety Information for Gas Permeable and Customized Soft Contact Lenses
WARNINGS:
Patients should be advised of the following warnings pertaining to contact lens wear:
CONTRAINDICATIONS:
Do not use when any of the following conditions exist:
ADVERSE EFFECTS:
The following problems may occur with the use of contact lenses:
About HOAs
HOAs are complex irregularities in the eye's lens or cornea that can significantly impact visual clarity. They result from factors such as irregularities in the corneal shape, scarring, previous eye surgeries, large pupils or certain medical conditions affecting the eye, such as keratoconus or other corneal dystrophies. They can also be induced by the aging process or from changes in the eye's internal structures. Patients who have HOAs can experience symptoms such as blurred vision, halos, glare and difficulty seeing in low light conditions such as driving at night.
About Bausch + Lomb
Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from birth through every phase of life. Its comprehensive portfolio of approximately 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with approximately 13,500 employees and a presence in approximately 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario, with corporate offices in Bridgewater, New Jersey. For more information, visit www.bausch.com and connect with us on Facebook, Instagram, LinkedIn, X and YouTube.
Reference
FocalPoints is a trademark of Advanced Medical.
All other product/brand names are trademarks of the respective owners.
© 2025 Bausch + Lomb.
ALZN.0026.USA.25
Last Trade: | US$11.52 |
Daily Change: | -0.24 -2.04 |
Daily Volume: | 149,131 |
Market Cap: | US$4.060B |
May 07, 2025 April 30, 2025 February 19, 2025 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREEnd of content
No more pages to load